

---

---

**Female condoms — Requirements and  
test methods**

*Préservatifs féminins — Exigences et méthodes d'essai*

**iTeh STANDARD PREVIEW**  
**(standards.iteh.ai)**

[ISO 25841:2011](https://standards.iteh.ai/catalog/standards/sist/3e6ebb62-0799-4e92-99ca-37a1420b75e5/iso-25841-2011)

<https://standards.iteh.ai/catalog/standards/sist/3e6ebb62-0799-4e92-99ca-37a1420b75e5/iso-25841-2011>



Reference number  
ISO 25841:2011(E)

## iTeh STANDARD PREVIEW (standards.iteh.ai)

[ISO 25841:2011](https://standards.iteh.ai/catalog/standards/sist/3e6ebb62-0799-4e92-99ca-37a1420b75e5/iso-25841-2011)

<https://standards.iteh.ai/catalog/standards/sist/3e6ebb62-0799-4e92-99ca-37a1420b75e5/iso-25841-2011>



### **COPYRIGHT PROTECTED DOCUMENT**

© ISO 2011

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office  
Case postale 56 • CH-1211 Geneva 20  
Tel. + 41 22 749 01 11  
Fax + 41 22 749 09 47  
E-mail [copyright@iso.org](mailto:copyright@iso.org)  
Web [www.iso.org](http://www.iso.org)

Published in Switzerland

# Contents

Page

Foreword .....	iv
Introduction.....	v
1 Scope .....	1
2 Normative references .....	1
3 Terms and definitions .....	1
4 Quality verification .....	3
5 Design .....	4
6 Barrier properties .....	6
7 Biocompatibility.....	6
8 Clinical (human use) investigations .....	7
9 Bursting volume and pressure .....	8
10 Tests for stability and shelf-life .....	8
11 Freedom from holes .....	9
12 Visible defects .....	9
13 Packaging and labelling.....	10
14 Data sheets .....	12
Annex A (normative) Sampling plans intended for assessing compliance of a continuing series of lots of sufficient number to allow the switching rules to be applied .....	13
Annex B (informative) Sampling plans intended for assessing compliance of isolated lots .....	14
Annex C (normative) Determination of lubricant mass for individual female condom containers .....	15
Annex D (normative) Determination of female condom length.....	17
Annex E (normative) Determination of female condom width .....	18
Annex F (normative) Determination of female condom thickness .....	19
Annex G (normative) Testing for female condom package integrity.....	20
Annex H (normative) Determination of barrier properties using the bacteriophage method .....	22
Annex I (normative) Determination of bursting volume and bursting pressure .....	27
Annex J (normative) Testing for holes .....	29
Annex K (normative) Determination of shelf-life by real-time stability studies .....	35
Annex L (informative) Guidance on conducting and analysing accelerated ageing studies .....	37
Bibliography.....	39

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 25841 was prepared by Technical Committee ISO/TC 157, *Non-systemic contraceptives and STI barrier prophylactics*.

## iTeh STANDARD PREVIEW (standards.iteh.ai)

[ISO 25841:2011](https://standards.iteh.ai/catalog/standards/sist/3e6ebb62-0799-4e92-99ca-37a1420b75e5/iso-25841-2011)

<https://standards.iteh.ai/catalog/standards/sist/3e6ebb62-0799-4e92-99ca-37a1420b75e5/iso-25841-2011>

## Introduction

A female condom is a sheath that completely lines the vaginal canal and is designated to be retained in the vagina during sexual intercourse and after withdrawal of the penis to prevent pregnancy and transmission of sexually transmitted infections (STIs).

A female condom is distinguished from a male condom in that it is retained in the vagina after withdrawal of the penis. The external component of the device can provide some coverage to the external female genitalia. Non-porous, intact, polymer films can be effective barriers to human immunodeficiency virus (HIV), other infectious agents responsible for the transmission of STIs and to spermatozoa. Female condoms made from polymer films can be effective for contraceptive purposes and in the prevention of STI transmission. To be effective, it is essential that female condoms completely line the vaginal canal, be free from holes and defects, have adequate physical properties so as not to break during use, are correctly packaged to protect them during storage and are correctly labelled to facilitate their use.

To be safe, it is essential that the female condom and any lubricant, additive, dressing, individual packaging material or powder applied to it neither contain nor liberate substances in amounts that are toxic, sensitizing, locally irritating or otherwise harmful under normal conditions of storage or use.

Female condoms are non-sterile medical devices, but manufacturers are advised to take appropriate precautions to minimize microbiological contamination of the product during manufacture and packaging. To ensure high quality products, it is essential that female condoms be designed and produced under a good quality management system. Reference can be made, for example, to ISO 9000, ISO 9001, ISO 9004, ISO 13485 and ISO 14971. To estimate the shelf-life of any new or modified female condom, manufacturers conduct stability tests before the product is placed on the market. This ensures that manufacturers have adequate data to support shelf-life claims and that these data are available for review by regulatory authorities, test laboratories and purchasers. They are also intended to limit the need for third parties to conduct long-term stability studies. Real-time shelf-life studies are also initiated, but not necessarily completed, prior to placing the product on the market.

Because female condoms are a relatively new class of devices and designs of female condoms vary considerably, clinical investigations in humans are necessary to continue to build evidence of safety and efficacy. These investigations enable an assessment of the overall performance of internal and external retention features, failure modes, safety and effectiveness of female condoms. This International Standard represents minimal requirements and test methods and acknowledges that new designs can require further due rigour of retention and other features as well as additional definition of specifications and test methods by the manufacturer.

All these issues are addressed in this International Standard.

## **iTeh STANDARD PREVIEW (standards.iteh.ai)**

ISO 25841:2011

<https://standards.iteh.ai/catalog/standards/sist/3e6ebb62-0799-4e92-99ca-37a1420b75e5/iso-25841-2011>

# Female condoms — Requirements and test methods

## 1 Scope

This International Standard specifies the minimum requirements and test methods for female condoms, which are supplied to consumers for contraceptive purposes assisting in the prevention of sexually transmitted infections.

## 2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 2859-1:1999, *Sampling procedures for inspection by attributes — Part 1: Sampling schemes indexed by acceptance quality limit (AQL) for lot-by-lot inspection*

ISO 4074, *Natural rubber latex condoms — Requirements and test methods*

ISO 10993-1, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 10993-5, *Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity*

ISO 10993-10, *Biological evaluation of medical devices — Part 10: Tests for irritation and skin sensitization*

ISO 10993-11, *Biological evaluation of medical devices — Part 11: Tests for systemic toxicity*

ISO 13485, *Medical devices — Quality management systems — Requirements for regulatory purposes*

ISO 14155 (all parts), *Clinical investigation of medical devices for human subjects*

ISO 14971, *Medical devices — Application of risk management to medical devices*

ISO 15223 (all parts), *Medical devices — Symbols to be used with medical device labels, labelling and information to be supplied*

## 3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 2859-1 and the following apply.

### 3.1

#### acceptance quality limit

#### AQL

quality level that is the worst tolerable process average when a continuing series of lots is submitted for acceptance sampling

[ISO 2859-1:1999, definition 3.1.26]

### 3.2

#### **consumer package**

package intended for distribution to a consumer, containing one or more individual container(s) of female condoms

### 3.3

#### **date of manufacture**

date of formation of the female condom sheath or the date the female condoms are packed in their individual containers provided, in the latter case, a maximum period of bulk storage is specified and shelf-life studies have been conducted on female condoms that have been subjected to the maximum bulk storage period

### 3.4

#### **expiry date**

date at the end of the shelf-life

### 3.5

#### **female condom**

sheath that completely lines the vaginal canal and is designed to be retained in the vagina during sexual intercourse to prevent pregnancy and transmission of sexually transmitted infections

### 3.6

#### **identification number**

number, or combination of numerals, symbols or letters used by a manufacturer on consumer packages to uniquely identify the lot numbers of individual female condoms contained in that package, and from which it is possible to trace those lots through all stages of manufacturing, packaging and distribution

NOTE Whenever the consumer package contains only one kind of female condom, the identification number can be the same as the lot number. However, if the consumer package contains several different types of female condoms, for instance, female condoms of different shapes or colours, the identification number is different from the lot number.

### 3.7

#### **individual container**

primary package containing a single female condom

### 3.8

#### **inspection level**

relationship between lot size and sample size

NOTE For description, see ISO 2859-1:1999, 10.1.

### 3.9

#### **lot**

collection of female condoms of the same design, colour, shape, size and formulation, manufactured at essentially the same time, using the same process, raw materials of the same specifications, common equipment and packed with the same lubricant and any other additive or dressing in the same type of individual container

NOTE This International Standard does not specify the size of a lot, however it is possible for a purchaser to do so as part of the purchasing contract. Attention is drawn to the difficulties that can be associated with the distribution and control of very large lots. The recommended maximum individual lot size for production is 500 000 female condoms.

### 3.10

#### **lot number**

number or combination of numerals, symbols or letters used by the manufacturer to identify a lot of individually packaged female condoms, and from which it is possible to trace that lot through all stages of manufacture up to packaging

### 3.11

#### **lot test**

test to assess the conformity of a lot

NOTE A lot test can be limited to include only those parameters that can change from lot to lot.



**3.12****non-visible hole**

hole in a female condom that is not visible under normal or corrected vision, but is detected by a suitable water leak test

NOTE 1 Leakage during testing can be detected, for instance, by rolling a female condom on absorbent paper.

NOTE 2 Suitable tests are specified in this International Standard.

**3.13****sampling plan**

specific plan that indicates the number of units of product from each lot which are to be inspected (sample size or series of sample sizes) and the associated criteria for determining the acceptability of the lot (acceptance and rejection numbers)

**3.14****shelf-life**

time from date of manufacture to the claimed expiry date during which condoms are required to conform to specified requirements

**3.15****total clinical failure**

sum of female condoms that clinically break or slip, or are associated with misdirection, invagination or any additional failure mode(s) identified in the risk assessment which results in reduction of the female condom protective function

NOTE Total clinical failure rate is calculated by dividing the number of female condoms with a clinical failure by the number of female condoms used during sexual intercourse.

**3.16****visible hole**

hole or tear in the female condom that is visible under normal or corrected vision

**3.17****visible defect**

⟨other than visible hole⟩ broken, missing or severely distorted retention feature, permanent crease with adhesion of the film or unintentional adhesion of the film to retention feature, including defect particles from female condoms or other materials embedded in the female condom wall

**4 Quality verification**

Female condoms are produced in large quantities. Inevitably, there is some variation between individual female condoms. A small proportion of female condoms in each production run might not meet the requirements in this International Standard. Furthermore, the majority of the test methods described in this International Standard are destructive. For these reasons, the only practicable method of assessing conformity with this International Standard is by testing a representative sample from a lot or series of lots. Basic sampling plans are identified in ISO 2859-1. See ISO/TR 8550 for guidance on the selection of an acceptance sampling system, scheme or plan for the inspection of discrete items in a lot. For testing purposes, sampling shall be conducted by lot number, not by identification number. Handling and storage conditions shall be documented before drawing the samples.

Sampling plans shall be selected to provide an acceptable level of consumer protection. Suitable sampling plans are given in Annexes A and B.

Annex A describes sampling plans, based on ISO 2859-1, and is most applicable to manufacturers or purchasers assessing the conformity of a continuing series of lots. The full level of consumer protection available depends upon the switch to tightened inspection if deterioration in quality is detected. The switching rules cannot offer full protection for the first two lots tested, but become progressively more effective as the

number of lots in a series increases. The sampling plans in Annex A are recommended when five or more lots are being tested.

Annex B describes sampling plans, based on ISO 2859-1, which are recommended for the assessment of isolated lots. It is recommended that these sampling plans be used for the assessment of fewer than five lots, for example in cases of dispute, for referee purposes, for type testing, for qualification purposes or for short runs of continuing series of lots.

It is necessary to know the lot size in order to derive from ISO 2859-1 the number of female condoms to be tested. The lot size varies among manufacturers and is regarded as part of the process and quality controls used by the manufacturer.

Instead of concentrating solely on evaluation of the final product, the design and manufacture of the female condoms shall conform to the appropriate requirements of ISO 13485, which include the following:

- a) controls in the work environment to ensure product safety;
- b) focus on risk-management activities and design transfer activities during product development;
- c) specific requirements for inspection and traceability for implantable devices;
- d) specific requirements for documentation and validation of processes for sterile medical devices;
- e) specific requirements for verification of the effectiveness of corrective and preventive actions.

## iTeh STANDARD PREVIEW (standards.iteh.ai)

### 5 Design

#### 5.1 General

<https://standards.iteh.ai/catalog/standards/sist/3e6abb62-0799-4e92-99ca-3791420b56e5/iso-25841-2011>

Female condoms shall be designed to prevent pregnancy and STIs during vaginal intercourse. A female condom is distinguished from a male condom in that it is retained in the vagina after insertion. A female condom may be made from natural rubber latex (NRL) or synthetic materials.

The design of a new female condom shall take into consideration the following design aspects:

- a) product insertion into the vagina;
- b) product retention during sexual intercourse or penile removal;
- c) penile misdirection during sexual intercourse;
- d) safe product removal after sexual intercourse.

#### 5.2 Product insertion feature

Designs for female condoms shall include either a feature or tool to aid in the proper insertion and deployment of the female condom or methods for insertion of the female condom without such additional aids.

The insertion feature design, materials and/or method shall be evaluated for function as part of design validation and clinical evaluation of the finished female condom device described in Clause 8.

The insertion feature materials shall be evaluated for biocompatibility (irritation, sensitization, cytotoxicity and acute systemic cytotoxicity) as an integrated feature of the finished female condom device in accordance with Clause 7.

Manufacturers shall identify specifications and test methods as appropriate to verify the design and to ensure the quality and consistency of components and materials used for each insertion feature. Examples of specifications the manufacturer should consider include critical dimensions, durometer, stiffness and density.

### 5.3 Retention features

Designs for female condoms shall incorporate intra-vaginal retention features to retain the female condom within the vagina during sexual intercourse and permit safe withdrawal after use. Intra-vaginal retention features can be affixed on or placed within the sheath. Examples of intra-vaginal retention mechanisms include, but are not limited to, elastomeric rings and open or closed cell foam components.

Designs for female condoms shall incorporate external retention features to keep the open end of the female condom open during sexual intercourse, prevent misdirection of penis and prevent female condom invagination. External retention features include, but are not limited to, annular, triangular or other-shaped components affixed to the open end of the female condom.

Retention feature designs, materials and/or methods shall be evaluated for function as part of design validation and clinical evaluation of the finished female condom device described in Clause 8. They shall also be evaluated in this manner to ensure the features stay affixed to the sheath or are retained within the sheath so that they remain intact during sexual intercourse and during product withdrawal, such that the features are completely removed from the vagina when the female condom is removed from the vagina.

Retention feature materials shall be evaluated for biocompatibility (irritation, sensitization and cytotoxicity) as an integrated feature of the finished female condom device in accordance with Clause 7.

Manufacturers shall identify specifications and test methods as appropriate to verify the design and to ensure the quality and consistency of components and materials used for each retention feature. Examples of specifications the manufacturer should consider include critical dimensions, durometer, stiffness and density.

### 5.4 Lubrication

**iTeh STANDARD PREVIEW**  
(standards.iteh.ai)

The design of a female condom may include lubrication in any of the following manners:

- a) lubricant pre-applied directly on the packaged female condom as supplied;  
<https://standards.iteh.ai/catalog/standards/sist/3e6ebb62-0799-4e92-99ca->
- b) lubricant supplied in a separate container for application to the female condom by the user;
- c) both pre-applied and as a separate container.

The type and amount of lubricant is unique to each female condom design. The manufacturer shall specify the range for the mass of lubricant consistent with the mass of lubricant used in the clinical trial described in Clause 8. When tested in accordance with the method given in Annex C, taking 13 female condoms from each lot, no female condom lubricant mass measurement shall be outside of the manufacturer's specified range.

Manufacturers shall identify specifications and test methods as appropriate to verify the design and to ensure the quality and consistency of the lubricant. Examples of specifications the manufacturer should consider include viscosity.

### 5.5 Dimensions

#### 5.5.1 Length

The length of a female condom is unique to each design. The manufacturer shall specify a nominal value and the range for the length of female condoms consistent with the length of the female condoms used in the clinical trial described in Clause 8. When tested in accordance with the method given in Annex D, taking 13 female condoms from each lot, no female condom length measurement shall be outside of the manufacturer's specified range.

#### 5.5.2 Width

The width of a female condom is unique to each design. The manufacturer shall specify the range for the width of the female condom consistent with the width of the female condoms used in the clinical trial described

in Clause 8. When tested in accordance with the method given in Annex E, taking 13 female condoms from each lot, no female condom width measurement shall be outside of the manufacturer's specified range.

### 5.5.3 Thickness

The thickness of a female condom is unique to each design. The range for the thickness of the female condom shall be specified by the manufacturer, based upon the female condoms that are used in the clinical trials. When tested by the method given in Annex F, taking 13 female condoms from each lot, no female condom thickness measurement shall be outside of the manufacturer's specified range (from the clinical trials).

## 5.6 Risk assessment

**5.6.1** A risk assessment for the product shall be conducted in accordance with ISO 14971. The assessment shall identify all potential failure modes for the device as well as any other safety and efficacy concerns. Failure modes identified in the risk analysis shall be compared to those listed in 5.6.2. In addition to these known failure modes, any new failure modes shall be assessed in the design and execution of any pre-clinical or clinical investigations of the female condom. Manufacturers shall make the results of the risk assessment available to regulatory authorities.

**5.6.2** The following are definitions of known female condom failure modes.

- a) Clinical breakage is defined as breakage during sexual intercourse or during withdrawal of the female condom from the vagina. Clinical breakage is breakage with potential adverse clinical consequences. The clinical breakage rate is calculated by dividing the number of female condoms reported to have broken during sexual intercourse or during withdrawal by the number of female condoms used during sexual intercourse.

NOTE Total breakage is defined as the sum of all female condom breakages at any time before, during or after sexual intercourse. It includes both clinical breakages and non-clinical breakages. The total breakage rate is calculated by dividing the total number of female condoms that broke by the number of female condom packages opened.

<https://standards.iteh.ai/catalog/standards/sist/3e6ebb62-0799-4e92-99ca-37a1420b75e5/iso-25841-2011>

- b) Slippage is defined as an instance when a female condom slips completely out of the vagina during sexual intercourse. The slippage rate is calculated by dividing the number of female condoms that slipped by the number of female condoms used during sexual intercourse.
- c) Misdirection is defined as vaginal penetration whereby the penis is inserted between the female condom and the vaginal wall. The misdirection rate is calculated by dividing the number of reported events of misdirection by the number of female condoms used during sexual intercourse.
- d) Invagination is defined as an instance when the external retention feature of the female condom is partially or fully pushed into the vagina during sexual intercourse. The invagination rate is calculated by dividing the number of events of invagination by the number of female condoms used during sexual intercourse.

## 6 Barrier properties

The barrier properties of the female condom shall be established by viral penetration studies using a suitable surrogate virus, for example bacteriophage phi-X 174. When tested in accordance with the method given in Annex H, viral penetration properties shall be compared with those of a male latex condom that meets the requirements of ISO 4074.

## 7 Biocompatibility

Biocompatibility for the finished product and its components shall be established. The female condom, together with any lubricant, additive, dressing material or powder applied to it, shall be tested as well as all

retention or insertion devices, whether affixed or removable. Accredited laboratories shall be used for the testing.

Since the female condom is in repeated contact with surface mucosa and possibly compromised tissue surfaces, the testing shall be conducted to demonstrate that the materials are neither cytotoxic nor cause sensitization, mucosal irritation or acute systemic cytotoxicity in accordance with the relevant clauses of ISO 10993-1, ISO 10993-5, ISO 10993-10 and ISO 10993-11, respectively. If there is a likelihood of systemic absorption of any components or residuals, mutagenicity testing shall be performed.

Regulatory bodies can require that the results be interpreted by a qualified toxicologist. The biological assessment report shall justify that the product is safe under normal conditions of use. All data generated in these evaluations shall be made available to regulatory authorities on request.

The manufacturer shall also obtain, and make available on request from regulatory authorities, toxicity data on all the additives and residual monomers, solvents and known impurities used in the manufacture of the female condom subject to this International Standard. Suitable material safety data sheets shall be supplied on request for materials used in the manufacture of products conforming with this International Standard.

## 8 Clinical (human use) investigations

**8.1** Clinical investigations of female condoms in humans shall be conducted in accordance with ISO 14155 (all parts), and are intended to be conducted with a future International Standard on functionality studies of acute failure events based on self-reports.

NOTE Clinical investigations can also be subject to local regulatory requirements.

**8.2** In order to assess the safety and effectiveness of a new female condom design, a contraceptive effectiveness study shall be conducted. The study design shall be adequate to determine the point estimate of the 12-month pregnancy rate for typical use with a 95 % confidence interval as required in the product labelling in Clause 13. The study should also measure all the rates of all failure modes identified in Clause 5.

**8.3** New female condom designs that are sufficiently similar to a design that is already approved and marketed may claim exemption from the requirement of 8.2. If a new female condom design and specifications are sufficiently similar to those of a marketed device and that marketed device has a known pregnancy rate established from a clinical effectiveness study, the manufacturer may refer to the estimated 12-month pregnancy rate of the marketed device instead of conducting a contraceptive effectiveness study on the new device. To claim exemption from the requirements of 8.2, the following requirements shall be met.

- a) The manufacturer shall conduct a risk analysis in accordance with 5.6.
- b) The manufacturer shall establish that the new female condom design and specifications are sufficiently similar to those of a marketed female condom, after assessing the impact of each difference in dimension, material, insertion and retention feature or method, on the incidence of each failure mode described in 5.6.2; on the incidence of new failure modes; and on the efficacy of the female condom in preventing pregnancy and STI transmission. Manufacturers shall make the results of this assessment available to regulatory authorities.
- c) The manufacturer shall conduct a randomized controlled clinical investigation comparing the new female condom to a control female condom and
  - 1) the control female condom shall meet the bursting volume and pressure, freedom from holes and visible defects requirements of Clauses 9, 11 and 12, and shall have a known pregnancy rate established from a clinical effectiveness study,
  - 2) the total clinical failure rate of the new female condom shall be shown to be non-inferior to the total clinical failure rate of the control female condom,
  - 3) the upper bound of the 95 % confidence interval for the new female condom total clinical failure rate minus the control female condom total clinical failure rate shall be less than or equal to 3 %,